Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aspirin + dipyridamole + clopidogrel
- Development stage
- Phase 3
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of three antiplatelet medications (aspirin, dipyridamole, and clopidogrel) that work through different mechanisms to prevent platelet aggregation and blood clot formation. This specific triple combination is not available as a fixed-dose product but represents a potential combination therapy approach that might be used in specific clinical scenarios.
- Other names
- Triple antiplatelet therapyIntensive antiplatelet therapyTARDIS triple therapy
02
Targets
ENT1 (Solute carrier family 29 member 1)PGHS-1 (Prostaglandin G/H Synthase 1)P2Y12 (Purinergic P2Y12 receptor)ENT (Equilibrative nucleoside transporter family)PDE (Phosphodiesterase family)
Beyond the preview
Go deeper on aspirin + dipyridamole + clopidogrel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aspirin + dipyridamole + clopidogrel.